Abecma 260 - 500 x 10^6 cells dispersion for infusion

DRUG3 trials

Sponsors

Universitaetsklinikum Wuerzburg AöR, Centre Hospitalier Universitaire De Saint Etienne, Universitaetsklinikum Erlangen AöR

Conditions

Chimeric antigen receptor T cell therapy-associated cytokine release syndromeProgressive systemic autoimmune disease resistant to B cell depletionhematology

Phase 1

A phase I/II, single arm, open label study of dasatinib as toxicity prophylaxis in the context of therapy with idecabtagene vicleucel in relapsed/refractory multiple myeloma

Not yet recruitingCTIS2023-507537-16-00

Universitaetsklinikum Wuerzburg AöRChimeric antigen receptor T cell therapy-associated cytokine release syndrome

Target: 55Updated: 2025-12-17

A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA

RecruitingCTIS2025-521530-28-00

Universitaetsklinikum Erlangen AöRProgressive systemic autoimmune disease resistant to B cell depletion

Start: 2026-01-19Target: 15Updated: 2025-11-17

Phase 4

Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector Cell-Associated Neurotoxicity Syndrome : the VESICANS study

RecruitingCTIS2024-515328-35-00

Centre Hospitalier Universitaire De Saint Etiennehematology

Start: 2025-07-02Target: 60Updated: 2025-04-17